Limits...
Long-term Effects of Specific Allergen Immunotherapy Against House Dust Mites in Polysensitized Patients With Allergic Rhinitis.

Kim SH, Shin SY, Lee KH, Kim SW, Cho JS - Allergy Asthma Immunol Res (2014)

Bottom Line: We evaluated the effectiveness of immunotherapy against house dust mites (HDMs) in AR patients polysensitized to both HDMs and seasonal allergens.There were no statistical differences in levels of total and specific IgE, or total eosinophil count between the two groups.We determined that the primary causative allergen of AR in Seoul, Korea is perennial allergens, such as HDMs, rather than seasonal allergens.

View Article: PubMed Central - PubMed

Affiliation: Department of Otorhinolaryngology-Head and Neck Surgery, School of Medicine, Kyung Hee University, Seoul, Korea.

ABSTRACT

Purpose: Allergen-specific immunotherapy is the only currently available treatment to modify the natural history of allergic rhinitis (AR). If patients are polysensitized, it is difficult to identify the allergen causing the allergic symptoms. We evaluated the effectiveness of immunotherapy against house dust mites (HDMs) in AR patients polysensitized to both HDMs and seasonal allergens.

Methods: Thirty AR patients polysensitized to both HDMs and seasonal allergens (group A) and 30 patients sensitized to HDMs only (group B) were enrolled in this study. All subjects who received immunotherapy against HDMs for more than 2 years were evaluated by the multiple allergen simultaneous test (MAST) to determine the specific IgE level in luminescence units, total eosinophil counts in peripheral blood, serum total IgE, total nasal symptom scores, and the rhinoconjunctivitis quality of life questionnaire (RQLQ) before and after immunotherapy.

Results: There were no statistical differences in levels of total and specific IgE, or total eosinophil count between the two groups. The total nasal symptom scores, RQLQ and medication scores significantly decreased after immunotherapy in both groups, however no significant differences were noted between the two groups.

Conclusions: We determined that the primary causative allergen of AR in Seoul, Korea is perennial allergens, such as HDMs, rather than seasonal allergens. This study provides a reference for the selection of allergens to use in immunotherapy for polysensitized AR patients living in an urban environment.

No MeSH data available.


Related in: MedlinePlus

Number of patients with severe allergic rhinitis symptoms during the season (*P<0.05).
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4214974&req=5

Figure 1: Number of patients with severe allergic rhinitis symptoms during the season (*P<0.05).

Mentions: The median age of patients in group A was 26 (range 15-42) years, and the average period of immunotherapy treatment was 31±9.2 months. The median age of patients in group B was 23 (range 17-39) years, and the average treatment period was 29±9.1 months. There were no significant differences in the baseline data, number of years with rhinitis symptoms, and periods of immunotherapy between the 2 groups (Table 1). The distribution of sensitized patients to specific allergens in each group is shown in Table 2. In group A, 4 patients were sensitized to 2 allergens, 5 to three allergens, 14 to 4 allergens, and 8 to 5 allergens. In the questionnaire on amelioration of seasonal nasal symptoms, group A showed a greater tendency for deterioration of symptoms than did group B, but there was no statistical significance. In addition, group B consisted of more patients whose symptoms continued regardless of the season (Fig. 1). MAST values (luminescence units) tended to increase after immunotherapy; however, statistical analyses could not be performed due to the small sample size of the target group (Table 2). After immunotherapy, 30% of patients in group A and 23% in group B showed new sensitization. In groups A and B, 4 and 3 patients were sensitized to new perennial allergens, respectively, and 5 and 4 were sensitized to new seasonal allergens, respectively; however, there was no significant difference between the 2 groups (Table 3).


Long-term Effects of Specific Allergen Immunotherapy Against House Dust Mites in Polysensitized Patients With Allergic Rhinitis.

Kim SH, Shin SY, Lee KH, Kim SW, Cho JS - Allergy Asthma Immunol Res (2014)

Number of patients with severe allergic rhinitis symptoms during the season (*P<0.05).
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4214974&req=5

Figure 1: Number of patients with severe allergic rhinitis symptoms during the season (*P<0.05).
Mentions: The median age of patients in group A was 26 (range 15-42) years, and the average period of immunotherapy treatment was 31±9.2 months. The median age of patients in group B was 23 (range 17-39) years, and the average treatment period was 29±9.1 months. There were no significant differences in the baseline data, number of years with rhinitis symptoms, and periods of immunotherapy between the 2 groups (Table 1). The distribution of sensitized patients to specific allergens in each group is shown in Table 2. In group A, 4 patients were sensitized to 2 allergens, 5 to three allergens, 14 to 4 allergens, and 8 to 5 allergens. In the questionnaire on amelioration of seasonal nasal symptoms, group A showed a greater tendency for deterioration of symptoms than did group B, but there was no statistical significance. In addition, group B consisted of more patients whose symptoms continued regardless of the season (Fig. 1). MAST values (luminescence units) tended to increase after immunotherapy; however, statistical analyses could not be performed due to the small sample size of the target group (Table 2). After immunotherapy, 30% of patients in group A and 23% in group B showed new sensitization. In groups A and B, 4 and 3 patients were sensitized to new perennial allergens, respectively, and 5 and 4 were sensitized to new seasonal allergens, respectively; however, there was no significant difference between the 2 groups (Table 3).

Bottom Line: We evaluated the effectiveness of immunotherapy against house dust mites (HDMs) in AR patients polysensitized to both HDMs and seasonal allergens.There were no statistical differences in levels of total and specific IgE, or total eosinophil count between the two groups.We determined that the primary causative allergen of AR in Seoul, Korea is perennial allergens, such as HDMs, rather than seasonal allergens.

View Article: PubMed Central - PubMed

Affiliation: Department of Otorhinolaryngology-Head and Neck Surgery, School of Medicine, Kyung Hee University, Seoul, Korea.

ABSTRACT

Purpose: Allergen-specific immunotherapy is the only currently available treatment to modify the natural history of allergic rhinitis (AR). If patients are polysensitized, it is difficult to identify the allergen causing the allergic symptoms. We evaluated the effectiveness of immunotherapy against house dust mites (HDMs) in AR patients polysensitized to both HDMs and seasonal allergens.

Methods: Thirty AR patients polysensitized to both HDMs and seasonal allergens (group A) and 30 patients sensitized to HDMs only (group B) were enrolled in this study. All subjects who received immunotherapy against HDMs for more than 2 years were evaluated by the multiple allergen simultaneous test (MAST) to determine the specific IgE level in luminescence units, total eosinophil counts in peripheral blood, serum total IgE, total nasal symptom scores, and the rhinoconjunctivitis quality of life questionnaire (RQLQ) before and after immunotherapy.

Results: There were no statistical differences in levels of total and specific IgE, or total eosinophil count between the two groups. The total nasal symptom scores, RQLQ and medication scores significantly decreased after immunotherapy in both groups, however no significant differences were noted between the two groups.

Conclusions: We determined that the primary causative allergen of AR in Seoul, Korea is perennial allergens, such as HDMs, rather than seasonal allergens. This study provides a reference for the selection of allergens to use in immunotherapy for polysensitized AR patients living in an urban environment.

No MeSH data available.


Related in: MedlinePlus